SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO.,LTD. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Stock
Equities
1349
CNE1000000W4
Pharmaceuticals
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.84 HKD | -2.13% |
|
-6.60% | -27.84% |
| Sales 2022 | 1.03B 142M 1.11B | Sales 2023 | 851M 117M 916M | Capitalization | 7.32B 1.01B 7.88B |
|---|---|---|---|---|---|
| Net income 2022 | 138M 19.03M 149M | Net income 2023 | 109M 15.03M 117M | EV / Sales 2022 | 5.52 x |
| Net cash position 2022 | 1.16B 161M 1.25B | Net cash position 2023 | 1.18B 162M 1.27B | EV / Sales 2023 | 7.22 x |
| P/E ratio 2022 |
23.6
x | P/E ratio 2023 |
22.1
x | Employees | 948 |
| Yield 2022 |
2.28% | Yield 2023 |
3.02% | Free-Float | 45.47% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.13% | ||
| 1 week | -6.60% | ||
| Current month | -10.68% | ||
| 1 month | -17.49% | ||
| 3 months | -19.65% | ||
| 6 months | -23.01% | ||
| Current year | -27.84% |
1 week
1.81
1.99
1 month
1.812.27
Current year
1.812.59
1 year
1.812.99
3 years
1.815.64
5 years
1.819.26
10 years
1.8112.64
| Managers | Title | Age | Since |
|---|---|---|---|
Jun Li
FOU | Founder | 55 | 96-11-10 |
Da Jun Zhao
FOU | Founder | 54 | 96-11-10 |
Yan Xue
DFI | Director of Finance/CFO | 43 | 10-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiao Yang Yu
BRD | Director/Board Member | 68 | 13-05-29 |
Bo Shen
BRD | Director/Board Member | 51 | 12-06-28 |
Xiao Long Liu
BRD | Director/Board Member | 67 | 16-05-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 32 M€ | +4.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 1.84 | -2.13% | 1 667 000 |
| 24-06-07 | 1.88 | +1.08% | 2,975,000 |
| 24-06-06 | 1.86 | -4.12% | 4,211,000 |
| 24-06-05 | 1.94 | -1.52% | 1,739,000 |
| 24-06-04 | 1.97 | -1.01% | 5,474,000 |
Delayed Quote Hong Kong S.E., June 10, 2024 at 11:53 pm EDT
More quotes
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is a China-based company mainly engaged in research and development, manufacturing and marketing of biomedicine. The Company's products include aminolevulinic acid hydrochloride topical powder (trade name: ALA) and hemporfin or injection (trade name: FuMeiDa), and doxorubicin hydrochloride liposome injection (trade name: LIBOd), among others. Its products are mainly used for skin venereal disease treatment and anti-tumor treatment. The Company conducts its businesses in the domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-18
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -27.84% | 730M | |
| +19.29% | 80.29B | |
| +15.30% | 9.2B | |
| -18.33% | 4.67B | |
| +43.39% | 4.49B | |
| +13.95% | 4.27B | |
| +10.89% | 2.25B | |
| -28.40% | 2.13B | |
| +15.93% | 2.1B | |
| -43.17% | 1.78B |
- Stock Market
- Equities
- 1349 Stock
